Drugs Discovery Assets:

SMA-MAP Biomarker Panel


Drugs Discovery Assets: SMA-MAP Biomarker Panel

The Spinal Muscular Atrophy (SMA) Foundation created a biomarker assay panel for SMA using Myriad RBM’s Multi-Analyte Profiling (MAP) technology platform. The SMA-MAP panel is a quantitative service measuring 27 plasma proteins associated with motor function and other outcome measures for SMA. These 27 markers have been evaluated in multiple SMA patient collections and several of these proteins are expressed in tissues that include the central nervous system and/or muscle. SMA-MAP provides a comprehensive and efficient platform to aid in the validation of biomarkers to help accelerate the development of new treatments for SMA. The panel is available for purchase from Myriad RBM.  For more information, please contact us at [email protected].